Affiliation:
1. People's Liberation Army Postgraduate Medical School
2. The Third Medical Center of Chinese PLA General Hospital
3. Nankai University
Abstract
Abstract
Cancer cells encounter unavoidable stress during tumor growth. The stress-induced transcription factor, activating transcription factor 4 (ATF4), has been reported to upregulate various adaptive genes involved in salvage pathways to alleviate stress and promote tumor progression. However, this effect is unknown in clear cell renal cell carcinoma (ccRCC). In this study, we found that ATF4 expression was remarkably upregulated in tumor tissues and associated with poor ccRCC outcomes. ATF4 depletion significantly impaired ccRCC cell proliferation, migration, and invasion in vitro and in vivo by inhibiting the AKT/mTOR and epithelial–mesenchymal transition (EMT)-related signaling pathway. RNA sequencing and functional studies identified nuclear protein 1 (NUPR1) as a key downstream target of ATF4 for repressing ferroptosis and promoting ccRCC cell survival. In addition, targeting ATF4 or pharmacological inhibition using NUPR1 inhibitor ZZW115 promoted antitumor immunity in syngeneic graft mouse models, represented by increased infiltration of CD4+ and CD8+ T cells. Furthermore, ZZW115 could improve the response to the PD-1 immune checkpoint blockade. The results demonstrate that the ATF4/NUPR1 signaling axis promotes ccRCC survival and facilitates tumor-mediated immunosuppression, providing a set of potential targets and prognostic indicators for ccRCC patients.
Publisher
Research Square Platform LLC
Reference71 articles.
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay J;Int J Cancer,2019
2. Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA Cancer J Clin. 2021;71(1):7–33.
3. Renal-cell carcinoma;Cohen HT;N Engl J Med,2005
4. SnapShot: Renal Cell Carcinoma;Ricketts CJ;Cancer Cell,2016
5. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update;Ljungberg B;Eur Urol,2022